WaiveDx

WaiveDx is a healthcare technology company at the forefront of diagnostics, genetics, and AI. We integrate CLIA-waived point-of-care tools with proprietary molecular testing and AI-driven platforms to deliver fast, accurate, and personalized care across clinical, legal, and wellness sectors. Our portfolio includes WellGenx, Waive IQ, NeuDefense, Velisce, and Precision Diagnostics—each focused on advancing outcomes in behavioral health, pharmacogenetics, supplementation, and clinical trials. With proprietary assets like Nymara™, PredictIQ™ and Synapta™, Velisce™, and a track record of regulatory success, WaiveDX empowers labs, providers, and government partners across the U.S. to scale with confidence.